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an aging population is upon us. Peripheral arterial disease
(PAD) is prevalent and has poor prognosis,1,2 but has been
neglected both in terms of research and primary preven-
tion.3,4 The disease has a strong age-related prevalence and
mortality, so, as the global number of individuals aged 75
years and over rapidly increases (119 million in 1990 to over
250 million currently), it has driven up the burden of this
disease substantially.5 The burden is long-term disability
more than premature mortality, with recent data showing
that both have increased signiﬁcantly over the last 20 years,
with increases being greatest in women, and in the devel-
oping nations.6
Currently over 200 million people are affected by this
condition worldwide, making it a global pandemic.7
Compared with HIV (another pandemic disease), PAD af-
fects six times as many individuals with a higher case-fa-
tality.8 Yet of all clinical trials performed in the last decade,
less than 2% were for PAD,9 and of these most have been
focused on novel devices and have been industry sponsored
and funded. When considering preventative research, trials
have largely omitted peripheral arterial events as a discrete
outcome measure; ascertained in only 11 out of the 91
largest blood pressure-lowering treatment trials over the
last two decades.10
Primary and secondary prevention continue to be grossly
under-utilised, despite good evidence for multiple strategies
in at-risk groups, including antiplatelet, statin, and antihy-
pertensive therapy, smoking cessation, and supervised ex-
ercise programmes.11e13 Cardio-embolic events account for
over 20% of all patients hospitalised with PAD. Anti-
coagulation is highly effective in the prevention of these
events,14 yet population-based data have shown that less
than 15% of patients suffering acute cardio-embolic pe-
ripheral arterial events are anticoagulated prior to event,
despite over 80% having CHA2DS2VASC scores 2 without
contraindications to anticoagulation.10
The leading seven risk factors for death in the UK across
all ages are poor diet, high blood pressure, smoking, high
body-mass index, physical inactivity, hyperlipidaemia, and
hyperglycaemia.15 These risk factors account for over 85%
of the attributable risk for atherosclerotic disease,16 and so,
although much of limited current research focuses on novel
biogenetic markers and invasive treatment options,
improving our understanding and treatment of traditional1078-5884/ 2015 European Society for Vascular Surgery. Published by
Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2015.07.015cardiovascular risk factors will have by far the greatest
impact on the outcome of PAD at a population level. As
recent evidence has shown that patients with PAD do not
receive the same intensity of atherosclerotic risk factor
intervention when compared with patients with isolated
coronary heart disease, it is clear that more needs to be
done.17
Unfortunately the end result of chronic academic and
clinical neglect are excessively high major amputation rates,
which have been realised in the UK and US recently.18,19 A
UK quality improvement framework and a recent National
Conﬁdential Enquiry into Patient Outcome and Death
(NCEPOD) review have focused on improving the care of
patients undergoing major limb amputation and reducing
mortality, but there are no policy documents in existence
that focus on the prevention of amputation. With over 100
major amputations being performed per week in the UK
and over half of these patients subsequently dying within 2
years, failure to target the root causes of PAD will inevitably
lead to ongoing preventable death and disability. From an
economic perspective, major amputation is one of the most
expensive interventions performed in any healthcare sys-
tem. When acute care costs, long-term rehabilitation, and
subsequent patient dependence are taken into account,
each procedure incurs an average economic cost of
$170,000 in the USA,19 with obvious major implications for
individuals, the health service, and economy.
More data are required on the incidence, risk factors,
levels of preventative treatment, and outcome for patients
with PAD to enable risk stratiﬁcation, inform patients about
risks and prognosis, facilitate health service planning, and
prevent excessive death and disability. It is high time to
focus on improving prevention rather than palliation and
close the stable doors before the horse has bolted.
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